Tunoxa´s optimized wound healing; production and market

Important results from the project

The aim of the project was to form the foundation for production and sale of high-end and customized wound care products that deliver optimal wound healing, minimal pain and prevent infection for burn patients . The products in focus have a unique proprietary technology base. The project has implemented a range of activities including laid the basis for decisions on classification , forthcoming CE marking , preparation of business plan after initial investment is made, and received the first positive results from pilot clinical testing.

Expected long term effects

The outcome of the project indicates that we are achieving the expected effects ; paving the way for the first investments, being able to start production and to initiate further clinical trials. In the work on production and the scale-up, negotiations with potential production partners commenced. As for clinical trials and testing on patient material, we have gone beyond our original goals and both initiated tests at Uppsala University Hospital and received the first positive results. These have led to a decision on further CE marking and a partner for this process has been identified.

Approach and implementation

The positive outcome of the project is based on access to a wide network of expertise and partnerships with a number of professional players incl. SP Process Development (for production and scale-up work), Potter Clarkson ( IP strategy development ) , MEDOS, NAMSA and Intertek Semko for advice on regulatory and CE marking and Dr. Fredrik Huss at the burn unit at the University Hospital for clinical tests. In addition, UU Innovation´s international network has facilitated important meetings and negotiations regarding investment and production.